I am a
Home I AM A Search Login

Papers of the Week

Papers: 27 Aug 2022 - 2 Sep 2022

Human Studies, Pharmacology/Drug Development

2022 Aug 29

J Headache Pain



Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.


McAllister P, Cohen JM, Ramirez Campos V, Ning X, Janka L, Barash S
J Headache Pain. 2022 Aug 29; 23(1):112.
PMID: 36038833.


Migraine is the second leading cause of disability worldwide. Although many preventive treatments reduce migraine frequency and severity, it is unclear whether these treatments reduce migraine-related disability in a clinically meaningful way. This pooled analysis evaluated the ability of fremanezumab to reduce migraine-related disability, based on responses and shifts in severity in patient-reported disability outcomes.